Michael Gold to Adenocarcinoma
This is a "connection" page, showing publications Michael Gold has written about Adenocarcinoma.
Connection Strength
0.131
-
A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study. Ann Oncol. 2019 09 01; 30(9):1487-1495.
Score: 0.131